TY - JOUR
T1 - A nano erythropoiesis stimulating agent for the treatment of anemia and associated disorders
AU - Das, Monojit
AU - Mondal, Susmita
AU - Ghosh, Ria
AU - Biswas, Pritam
AU - Moussa, Ziad
AU - Darbar, Soumendra
AU - Ahmed, Saleh A.
AU - Das, Anjan Kumar
AU - Bhattacharya, Siddhartha Sankar
AU - Pal, Debasish
AU - Mallick, Asim Kumar
AU - Chakrabarti, Prantar
AU - Kundu, Jayanta Kumar
AU - Adhikari, Aniruddha
AU - Pal, Samir Kumar
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/9/16
Y1 - 2022/9/16
N2 - The usual treatment for anemia and especially for anemia of inflammation (also called anemia of chronic disease) is supportive care with the target of improving the lifestyle of the patients. There is no effective medication to date for proper management. As the inflammation, erythropoiesis, and oxidative stress are the major concerns in this case, it inspired us to use a nano-erythropoietin stimulating agent (nano-ESA) made up of a nano-complex of manganese and citrate (Mn-citrate nano-complex), which has been hypothesized to have excellent antioxidant and anti-inflammatory mechanisms. Single oral dose of the nano-ESA efficiently prevented the onset of anemia as well as led to recovery from anemia in our phenylhydrazine (PHz)-intoxicated C57BL/6J mice model of anemia without any toxicological side effects. These preliminary findings may pave the way for an affordable and safe clinical use of the nano-ESA as a rapid recovery medication of anemia, especially anemia of inflammation.
AB - The usual treatment for anemia and especially for anemia of inflammation (also called anemia of chronic disease) is supportive care with the target of improving the lifestyle of the patients. There is no effective medication to date for proper management. As the inflammation, erythropoiesis, and oxidative stress are the major concerns in this case, it inspired us to use a nano-erythropoietin stimulating agent (nano-ESA) made up of a nano-complex of manganese and citrate (Mn-citrate nano-complex), which has been hypothesized to have excellent antioxidant and anti-inflammatory mechanisms. Single oral dose of the nano-ESA efficiently prevented the onset of anemia as well as led to recovery from anemia in our phenylhydrazine (PHz)-intoxicated C57BL/6J mice model of anemia without any toxicological side effects. These preliminary findings may pave the way for an affordable and safe clinical use of the nano-ESA as a rapid recovery medication of anemia, especially anemia of inflammation.
KW - Medical biochemistry
KW - Molecular medicine
KW - Nanotechnology
UR - http://www.scopus.com/inward/record.url?scp=85137414157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137414157&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2022.105021
DO - 10.1016/j.isci.2022.105021
M3 - Article
AN - SCOPUS:85137414157
SN - 2589-0042
VL - 25
JO - iScience
JF - iScience
IS - 9
M1 - 105021
ER -